Latest Headlines

Latest Headlines

Japan's Eisai receives $40M in revised cancer therapy deal with Epizyme

Japan's Eisai sold the worldwide rights, excluding Japan, to Phase I/II cancer candidate EP-6438 to U.S.-based Epizyme for $40 million upfront, revising a 2011 agreement on discovery, development and commercialization of a therapy aimed at non-Hodgkin B-cell lymphoma and other cancers.

Can Eisai pump its thyroid cancer pill to $1B in sales? Rival Bayer might object

Eisai won speedy FDA approval for its new cancer drug Lenvima, eyeing $1 billion in potential sales and setting the stage for a showdown with Bayer's cancer-fighter Nexavar.

Eisai nabs quick FDA blessing for cancer blockbuster hopeful Lenvima

Eisai grabbed an early green light on Friday from U.S. regulators for thyroid cancer drug Lenvima, meaning the Japanese pharma can now get an earlier-than-expected start on trying to make its blockbuster dreams a reality.

Eisai wins an early FDA nod for its self-described cancer blockbuster

Eisai is counting on its new cancer drug to eventually bring in more than $1 billion a year, and now, thanks to an early FDA approval, the Japanese drugmaker has a head start on making that a reality.

Eisai says its new thyroid cancer drug is a sure blockbuster

Eisai, on the mend after some big patent losses, believes its top prospect in oncology can bring in peak annual sales north of $1 billion, beginning with thyroid cancer and expanding to treat other tumor types.

Eisai's copay offer on Belviq has unintended consequences for Arena

As competition in the obesity drug space ramps up, Arena's marketing partner Eisai is rolling out a new savings card for weight-loss drug Belviq. And for the California drugmaker, that means good news and bad news for its revenue outlook.

Big Pharma threatens to sue U.K. fund as officials nix Novartis, Sanofi and Eisai meds

U.K. officials have decided which drugs to toss off the Cancer Drug Fund, which pays for drugs rejected by cost-effectiveness gatekeepers. Reportedly, Novartis, Sanofi and Eisai treatments are among them.

Arena, Eisai have to recall nearly 122,000 bottles of Belviq over labeling glitch

Arena Pharmaceuticals has seen sales of its weight-loss drug Belviq improve since teaming up with marketing partner Eisai. But the two have hit a manufacturing stumbling block, having to voluntarily recall three lots of the drug because of labeling issues.

Eisai opens new plants targeting Asia and Europe

Japanese drugmaker Eisai opened two new plants--one targeting products for Asia and the other aimed at Europe--as part of its plans to expand its global manufacturing operations.

Eisai 'speechless' after another Fycompa price smack-down from Germany

Germany's cost-effectiveness gatekeepers have delivered another blow to Eisai over the price of Fycompa. And the verdict, just the drugmaker's latest frustration over the epilepsy drug, has left it "speechless" and "dismayed."